Theravance Biopharma, Inc.TBPHNASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
-136.88%
↓ 3881% below average
Average (39q)
-3.44%
Historical baseline
Range
High:81.12%
Low:-136.88%
CAGR
+4.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -136.88% |
| Q2 2025 | 81.12% |
| Q1 2025 | -56.89% |
| Q4 2024 | 15.11% |
| Q3 2024 | 31.00% |
| Q2 2024 | -40.14% |
| Q1 2024 | -79.60% |
| Q4 2023 | 28.77% |
| Q3 2023 | 45.67% |
| Q2 2023 | 35.28% |
| Q1 2023 | -42.92% |
| Q4 2022 | -22.74% |
| Q3 2022 | 38.52% |
| Q2 2022 | 37.94% |
| Q1 2022 | 33.73% |
| Q4 2021 | -4.76% |
| Q3 2021 | 16.37% |
| Q2 2021 | 23.58% |
| Q1 2021 | -9.68% |
| Q4 2020 | 0.16% |
| Q3 2020 | -6.15% |
| Q2 2020 | 0.41% |
| Q1 2020 | -2.70% |
| Q4 2019 | -8.24% |
| Q3 2019 | -53.50% |
| Q2 2019 | 42.34% |
| Q1 2019 | -17.64% |
| Q4 2018 | -0.27% |
| Q3 2018 | -28.22% |
| Q2 2018 | 25.04% |
| Q1 2018 | 17.93% |
| Q4 2017 | -38.91% |
| Q3 2017 | 12.48% |
| Q2 2017 | -10.70% |
| Q1 2017 | -1.72% |
| Q4 2016 | -72.67% |
| Q3 2016 | 29.48% |
| Q2 2016 | -14.06% |
| Q1 2016 | 25.34% |
| Q4 2015 | -29.42% |